Edwards Lifesciences Corp (NYSE:EW) – Stock analysts at William Blair raised their Q2 2020 EPS estimates for shares of Edwards Lifesciences in a report released on Friday, December 6th. William Blair analyst M. Kaczor now anticipates that the medical research company will earn $1.53 per share for the quarter, up from their prior forecast of $1.51. William Blair also issued estimates for Edwards Lifesciences’ Q3 2020 earnings at $1.51 EPS, FY2020 earnings at $6.11 EPS, Q1 2021 earnings at $1.61 EPS, Q2 2021 earnings at $1.69 EPS, Q3 2021 earnings at $1.62 EPS and FY2021 earnings at $6.70 EPS.
A number of other research analysts have also recently commented on EW. Cowen upped their target price on Edwards Lifesciences from $250.00 to $265.00 and gave the company a “positive” rating in a research note on Thursday, October 24th. Jefferies Financial Group raised their price target on Edwards Lifesciences from $255.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. ValuEngine cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Raymond James boosted their price objective on Edwards Lifesciences from $255.00 to $263.00 and gave the company an “outperform” rating in a report on Friday. Finally, Royal Bank of Canada upped their price objective on Edwards Lifesciences from $217.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $237.33.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm posted $1.07 EPS. The firm’s revenue was up 20.7% compared to the same quarter last year.
A number of large investors have recently modified their holdings of EW. TRUE Private Wealth Advisors bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth $26,000. Quest Capital Management Inc. ADV purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $28,000. Next Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 297.7% during the 2nd quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock worth $32,000 after purchasing an additional 128 shares during the last quarter. Tarbox Family Office Inc. boosted its position in Edwards Lifesciences by 48.7% during the second quarter. Tarbox Family Office Inc. now owns 177 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 58 shares in the last quarter. Finally, Usca Ria LLC bought a new stake in Edwards Lifesciences during the third quarter valued at about $34,000. 80.87% of the stock is owned by institutional investors.
In other news, VP Larry L. Wood sold 6,716 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $218.24, for a total transaction of $1,465,699.84. Following the transaction, the vice president now directly owns 124,145 shares in the company, valued at $27,093,404.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $214.90, for a total transaction of $4,910,465.00. Following the transaction, the chief executive officer now directly owns 95,770 shares in the company, valued at $20,580,973. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 119,151 shares of company stock valued at $27,606,089. 1.63% of the stock is currently owned by corporate insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: What does an outperform rating mean?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.